Opportunity Information: Apply for PA 08 157
Apply for PA 08 157
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Biomarkers of Infection Associated Cancers (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Apr 22, 2008.
- Applicants must submit their applications by May 7, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Public and State controlled institutions of higher education State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Hispanic serving Institutions Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Biomarkers of Infection Associated Cancers (R21) opportunity (Funding Opportunity Number PA-08-157) was a National Institutes of Health (NIH) funding announcement led by the National Cancer Institute (NCI) together with the National Institute of Dental and Craniofacial Research (NIDCR). Its central goal was to spur early-stage, exploratory research aimed at identifying biomarkers for cancers that are caused, triggered, or strongly driven by infectious agents. In practical terms, the FOA was looking for projects that could discover, develop, or begin to validate measurable biological indicators that link infection to cancer risk, early detection, diagnosis, or disease characterization. The emphasis on infection-associated cancers reflects the public health importance of malignancies where pathogens play a causal role, and where better biomarkers could improve screening strategies, triage, prognosis, and prevention efforts.
This announcement used the NIH Exploratory/Developmental Grant mechanism (R21), which is typically designed for innovative, higher-risk ideas that may not yet have extensive preliminary data. The R21 structure supports proof-of-concept work, feasibility testing, pilot data collection, and early biomarker discovery or refinement that could later be expanded into larger studies. The FOA was described as running in parallel with another solicitation of the same scientific scope (PA-08-156) that used the more traditional R01 mechanism, giving applicants a choice between an exploratory pathway (R21) and a fuller-scale research project pathway (R01), depending on the maturity and scale of the proposed work.
In terms of funding, the announcement set an award ceiling of $200,000 (as listed in the source data). The NIH noted that awards would depend on the availability of funds and the receipt of sufficiently strong applications, and it did not specify an expected number of awards. It also flagged that both the size and duration of awards could vary from project to project because biomarker research can range widely in scope, methods, and resource needs. In other words, the final portfolio and total dollars awarded were intended to be driven by scientific merit, project timelines, and justified budgets rather than a fixed quota.
The opportunity was categorized as a discretionary grant and mapped to health and education-related funding activity areas. It referenced multiple CFDA program areas, including Oral Diseases and Disorders Research (93.121) and several cancer-related categories (93.393 Cancer Cause and Prevention Research; 93.394 Cancer Detection and Diagnosis Research; 93.396 Cancer Biology Research). This mix signaled broad relevance, including cancers with oral or craniofacial relevance as well as general oncology applications spanning etiology, biology, prevention, detection, and diagnosis. There was no cost sharing or matching requirement, meaning applicants were not required to contribute non-federal funds as a condition of receiving an award.
Eligibility was broad and included many common NIH applicant types: public and state-controlled institutions of higher education, private institutions of higher education, state governments, small businesses, other for-profit organizations (beyond small businesses), and nonprofits both with and without 501(c)(3) status (with the listed caveats). Additional eligible applicant categories also included certain federal agencies, Hispanic-serving institutions, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). The inclusion of foreign organizations and regional bodies suggested NIH interest in global collaboration and in studying infection-associated cancers that may have high burdens in particular regions or populations.
Administratively, the FOA was posted on April 22, 2008, and ultimately closed on May 7, 2011, with an archive date of June 7, 2011. The sponsoring agency listed was NIH. The full announcement was available through the NIH grants guide page associated with PA-08-157, and NIH’s Office of Extramural Research (OER) webmaster contact was provided for access or linking issues. Overall, the grant was meant to catalyze innovative biomarker work at an early stage, specifically focused on cancers tied to infectious causes, with the expectation that promising findings could later support more definitive studies and, eventually, clinical or public health impact.
Frequently Asked Questions (FAQs): Biomarkers of Infection Associated Cancers (R21) - PA-08-157
What is the Biomarkers of Infection Associated Cancers (R21) opportunity (PA-08-157)?
PA-08-157 was a National Institutes of Health (NIH) funding opportunity announcement (FOA) focused on early-stage, exploratory research to identify biomarkers for cancers that are caused, triggered, or strongly driven by infectious agents. It used the NIH Exploratory/Developmental Grant mechanism (R21).
Which NIH institutes led this funding announcement?
The FOA was led by the National Cancer Institute (NCI) together with the National Institute of Dental and Craniofacial Research (NIDCR), under the NIH.
What types of cancers were the focus of this FOA?
The scientific focus was on infection-associated cancers, meaning malignancies where pathogens play a causal role or strongly drive cancer development. The intent was to improve how these cancers are understood, detected, characterized, and potentially prevented using biomarkers linked to infection.
What is the central goal of the FOA?
The central goal was to spur innovative, early-stage research aimed at discovering, developing, or beginning to validate measurable biological indicators (biomarkers) that connect infection to cancer risk, early detection, diagnosis, or disease characterization.
What kinds of biomarker-related work did the announcement emphasize?
The FOA emphasized projects that could discover biomarkers, develop them further, or begin to validate them, particularly where those biomarkers could be used for screening strategies, triage, prognosis, prevention efforts, or improved understanding of disease linked to infectious causes.
What does the R21 mechanism mean in practical terms?
The R21 is an NIH Exploratory/Developmental Grant mechanism intended to support innovative, higher-risk research ideas that may not yet have extensive preliminary data. It commonly supports proof-of-concept studies, feasibility testing, pilot data collection, and early biomarker discovery or refinement.
Was extensive preliminary data required to apply?
The FOA described the R21 mechanism as supporting higher-risk ideas that may not yet have extensive preliminary data, aligning the opportunity with exploratory and developmental work.
Was there a related R01 opportunity for the same scientific scope?
Yes. The FOA was described as running in parallel with PA-08-156, which covered the same scientific scope but used the traditional R01 mechanism. This setup gave applicants a choice between an exploratory pathway (R21) and a fuller-scale project pathway (R01), depending on the maturity and scale of the proposed research.
What was the maximum award amount listed for PA-08-157?
The announcement set an award ceiling of $200,000 (as listed in the source data).
Did the FOA specify the number of awards NIH expected to make?
No. NIH did not specify an expected number of awards. Awards were dependent on the availability of funds and the receipt of sufficiently strong applications.
Could the size and duration of awards vary by project?
Yes. The FOA noted that both award size and duration could vary because biomarker research can differ widely in scope, methods, and resource needs. The final amounts and timelines were intended to be driven by scientific merit, project timelines, and justified budgets rather than a fixed quota.
What type of funding was this categorized as?
The opportunity was categorized as a discretionary grant.
Which funding activity areas did this FOA relate to?
It was mapped to health and education-related funding activity areas.
Which CFDA program areas were referenced?
The FOA referenced multiple CFDA program areas, including Oral Diseases and Disorders Research (93.121) and several cancer-related categories: 93.393 (Cancer Cause and Prevention Research), 93.394 (Cancer Detection and Diagnosis Research), and 93.396 (Cancer Biology Research).
What does the mix of CFDA areas suggest about the scope of projects?
The mix signaled broad relevance, including cancers with oral or craniofacial relevance (reflecting NIDCR involvement) as well as general oncology applications spanning cancer etiology, biology, prevention, detection, and diagnosis.
Was cost sharing or matching required?
No. The FOA stated there was no cost sharing or matching requirement, meaning applicants were not required to contribute non-federal funds as a condition of receiving an award.
Which organizations were eligible to apply?
Eligibility was broad and included: public and state-controlled institutions of higher education; private institutions of higher education; state governments; small businesses; other for-profit organizations (beyond small businesses); and nonprofits both with and without 501(c)(3) status (with listed caveats). Additional eligible categories included certain federal agencies, Hispanic-serving institutions, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations).
Were foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA explicitly included non-U.S. entities (foreign organizations) among eligible applicants, indicating openness to international participation.
Why might the FOA have included foreign organizations and regional bodies?
The inclusion suggested an NIH interest in global collaboration and in studying infection-associated cancers that may have higher burdens in specific regions or populations.
When was PA-08-157 posted and when did it close?
The FOA was posted on April 22, 2008, and closed on May 7, 2011. The archive date was June 7, 2011.
Which agency was listed as the sponsoring agency?
The sponsoring agency listed was the National Institutes of Health (NIH).
Where could applicants find the full announcement?
The full announcement was available through the NIH grants guide page associated with PA-08-157.
Who was listed as a contact for access or linking issues?
NIH’s Office of Extramural Research (OER) webmaster contact was provided for access or linking issues related to the announcement page.
What broader impact was the FOA aiming for?
The FOA was intended to catalyze innovative biomarker work at an early stage for cancers tied to infectious causes, with the expectation that promising findings could later support more definitive studies and ultimately contribute to clinical or public health impact.
Browse more opportunities from the same category: Education Health
Next opportunity: Mouse Models Containing Human Alleles Novel Tools to Study Brain Function (R21/R33)
Previous opportunity: Biomarkers of Infection Associated Cancers (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 08 157
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 08 157) also looked into and applied for these:
| Funding Opportunity |
|---|
| Transdisciplinary Research on Fatigue and Fatigability in Aging (R01) Apply for PA 08 161 Funding Number: PA 08 161 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Transdisciplinary Research on Fatigue and Fatigability in Aging (R21) Apply for PA 08 162 Funding Number: PA 08 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Stem Cells and Cancer (R21) Apply for PA 08 165 Funding Number: PA 08 165 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Economics of Treatment and Prevention Services for Drug Alcohol Abuse (R03) Apply for PA 08 172 Funding Number: PA 08 172 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Economics of Treatment and Prevention Services for Drug Alcohol Abuse (R01) Apply for PA 08 174 Funding Number: PA 08 174 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Novel Lentiviral Models of HIV Neuropathogenesis (R01) Apply for PAS 08 178 Funding Number: PAS 08 178 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Novel Lentiviral Models of HIV Neuropathogenesis (R21) Apply for PAS 08 179 Funding Number: PAS 08 179 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory/Developmental Grant for Complementary and Alternative Medicine (CAM) Studies using Cells, Tissues, and Animal Models of Disease (R21) Apply for PA 08 185 Funding Number: PA 08 185 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Medications Development for Polydrug Addiction Treatment (R01) Apply for PAS 08 186 Funding Number: PAS 08 186 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for Polydrug Addiction Treatment (R21) Apply for PAS 08 187 Funding Number: PAS 08 187 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Integrating Biobehavioral and Sociocultural Research to Prevent HIV Transmission and Infection (R01) Apply for PA 08 188 Funding Number: PA 08 188 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Integrating Biobehavioral and Sociocultural Research to Prevent HIV Transmission and Infection (R21) Apply for PA 08 189 Funding Number: PA 08 189 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Geographic and Contextual Influences on Energy Balance Related Health Behaviors (R01) Apply for PA 08 192 Funding Number: PA 08 192 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Geographic and Contextual Influences on Energy Balance Related Health Behaviors (R21) Apply for PA 08 193 Funding Number: PA 08 193 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technological Innovations for Interdisciplinary Research Incorporating the Behavioral and Social Sciences (STTR R41/R42) Apply for PAR 08 201 Funding Number: PAR 08 201 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Pilot studies in Pancreatic Cancer (R21) Apply for PA 08 208 Funding Number: PA 08 208 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| PPilot studies in Pancreatic Cancer (R03) Apply for PA 08 209 Funding Number: PA 08 209 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diet Induced Changes in Inflammation as Determinants of Colon Cancer (R01) Apply for PA 08 210 Funding Number: PA 08 210 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diet Induced Changes in Inflammation as Determinants of Colon Cancer (R21) Apply for PA 08 211 Funding Number: PA 08 211 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Abuse Prevention Intervention Research (R01) Apply for PA 08 217 Funding Number: PA 08 217 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 157", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
